Neurodegenerative Diseases

R&D

Cell work representation, under a microscope

Unlocking the future of neurodegeneration research: How auto...

On the emergence of brain organoids and the advent of automation, the latter being essential for high-throughput approaches drug development demands.

News

Alector ditches GSK-partnered dementia drug and cuts staff

Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.

R&D

Alzheimer’s research: Cutting through the noise to find the ...

A closer look at how clinical trials for Alzheimer’s have evolved and what this means for patients and sites, with Medidata and Cogstate.

News

Joy as uniQure Huntington's therapy clears pivotal trial

uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.

News

Bayer starts pivotal Parkinson's cell therapy trial

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

Unlocking the future of neurodegeneration research: How auto...

Alector ditches GSK-partnered dementia drug and cuts staff

Alzheimer’s research: Cutting through the noise to find the ...

Joy as uniQure Huntington's therapy clears pivotal trial

Bayer starts pivotal Parkinson's cell therapy trial

NRG raises £50m to start trials of Parkinson's, ALS drug

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Neurodegenerative Diseases

Editor's Picks